These data indicate that a combination adjuvant including a synthetic TLR4 agonist and a lipidated TLR7/8 agonist induces better protection against influenza-induced weight loss than a TLR4 adjuvant or a TLR7/8 agonist alone (Figure 5C). The gene discussed is TLR4; the disease is influenza.